Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: stearic acid; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; stearic acid; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 80 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica - indicated for the treatment of diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; hypromellose; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaforte (malaysia) sdn. bhd. - gliclazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maltodextrin; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Canada - English - Health Canada

mylan pharmaceuticals ulc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas

Canada - English - Health Canada

sun pharma canada inc - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas

Canada - English - Health Canada

sun pharma canada inc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas

Canada - English - Health Canada

apotex inc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas